House Dust Mite Allergy
3
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
InmunotekSpain - Madrid
1 program1
MM09 allergoid-mannan conjugates subcutaneousPhase 31 trial
Active Trials
Hal AllergyNetherlands - Leiden
2 programsSUBLIVAC FIX Mite mixturePHASE_1_2
PURETHAL Mites 50,000 AUeq/mlPHASE_3
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergopharmahouse dust mite allergen extract
InmunotekMM09 allergoid-mannan conjugates subcutaneous
Clinical Trials (2)
Total enrollment: 400 patients across 2 trials
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
Start: Sep 2002Est. completion: Feb 2006
Phase 4Completed
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
Start: Dec 2022Est. completion: Jul 2025400 patients
Phase 3Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.